Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab

Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the e...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Horikoshi, Masanobu [verfasserIn] Ito, Satoshi [verfasserIn] Ishikawa, Mizue [verfasserIn] Umeda, Naoto [verfasserIn] Kondo, Yuya [verfasserIn] Tsuboi, Hiroto [verfasserIn] Hayashi, Taichi [verfasserIn] Goto, Daisuke [verfasserIn] Matsumoto, Isao [verfasserIn] Sumida, Takayuki [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2009

Schlagwörter:	Infliximab Mizoribine Rheumatoid arthritis

Übergeordnetes Werk:	Enthalten in: Modern rheumatology - Oxford : Oxford University Press, 2000, 19(2009), 3 vom: 27. März, Seite 229-234
Übergeordnetes Werk:	volume:19 ; year:2009 ; number:3 ; day:27 ; month:03 ; pages:229-234

Links:	Volltext

DOI / URN:	10.1007/s10165-009-0162-4

Katalog-ID:	SPR009021809

Internformat


LEADER	01000caa a22002652 4500
001	SPR009021809
003	DE-627
005	20230519115549.0
007	cr uuu---uuuuu
008	201005s2009 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10165-009-0162-4 \|2 doi
035			\|a (DE-627)SPR009021809
035			\|a (SPR)s10165-009-0162-4-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
082	0	4	\|a 610 \|q ASE
084			\|a 44.83 \|2 bkl
100	1		\|a Horikoshi, Masanobu \|e verfasserin \|4 aut
245	1	0	\|a Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab
264		1	\|c 2009
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics.
650		4	\|a Infliximab \|7 (dpeaa)DE-He213
650		4	\|a Mizoribine \|7 (dpeaa)DE-He213
650		4	\|a Rheumatoid arthritis \|7 (dpeaa)DE-He213
700	1		\|a Ito, Satoshi \|e verfasserin \|4 aut
700	1		\|a Ishikawa, Mizue \|e verfasserin \|4 aut
700	1		\|a Umeda, Naoto \|e verfasserin \|4 aut
700	1		\|a Kondo, Yuya \|e verfasserin \|4 aut
700	1		\|a Tsuboi, Hiroto \|e verfasserin \|4 aut
700	1		\|a Hayashi, Taichi \|e verfasserin \|4 aut
700	1		\|a Goto, Daisuke \|e verfasserin \|4 aut
700	1		\|a Matsumoto, Isao \|e verfasserin \|4 aut
700	1		\|a Sumida, Takayuki \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Modern rheumatology \|d Oxford : Oxford University Press, 2000 \|g 19(2009), 3 vom: 27. März, Seite 229-234 \|w (DE-627)320627497 \|w (DE-600)2023498-3 \|x 1439-7609 \|7 nnns
773	1	8	\|g volume:19 \|g year:2009 \|g number:3 \|g day:27 \|g month:03 \|g pages:229-234
856	4	0	\|u https://dx.doi.org/10.1007/s10165-009-0162-4 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_40
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_151
912			\|a GBV_ILN_170
912			\|a GBV_ILN_224
912			\|a GBV_ILN_267
912			\|a GBV_ILN_285
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
936	b	k	\|a 44.83 \|q ASE
951			\|a AR
952			\|d 19 \|j 2009 \|e 3 \|b 27 \|c 03 \|h 229-234

Indexfelder

author_variant	m h mh s i si m i mi n u nu y k yk h t ht t h th d g dg i m im t s ts
matchkey_str	article:14397609:2009----::fiayfioiieusteaynainsihhuaodrhiiwohwrdcdrn
hierarchy_sort_str	2009
bklnumber	44.83
publishDate	2009
allfields	10.1007/s10165-009-0162-4 doi (DE-627)SPR009021809 (SPR)s10165-009-0162-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Horikoshi, Masanobu verfasserin aut Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics. Infliximab (dpeaa)DE-He213 Mizoribine (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Ito, Satoshi verfasserin aut Ishikawa, Mizue verfasserin aut Umeda, Naoto verfasserin aut Kondo, Yuya verfasserin aut Tsuboi, Hiroto verfasserin aut Hayashi, Taichi verfasserin aut Goto, Daisuke verfasserin aut Matsumoto, Isao verfasserin aut Sumida, Takayuki verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 19(2009), 3 vom: 27. März, Seite 229-234 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:19 year:2009 number:3 day:27 month:03 pages:229-234 https://dx.doi.org/10.1007/s10165-009-0162-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 19 2009 3 27 03 229-234
spelling	10.1007/s10165-009-0162-4 doi (DE-627)SPR009021809 (SPR)s10165-009-0162-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Horikoshi, Masanobu verfasserin aut Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics. Infliximab (dpeaa)DE-He213 Mizoribine (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Ito, Satoshi verfasserin aut Ishikawa, Mizue verfasserin aut Umeda, Naoto verfasserin aut Kondo, Yuya verfasserin aut Tsuboi, Hiroto verfasserin aut Hayashi, Taichi verfasserin aut Goto, Daisuke verfasserin aut Matsumoto, Isao verfasserin aut Sumida, Takayuki verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 19(2009), 3 vom: 27. März, Seite 229-234 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:19 year:2009 number:3 day:27 month:03 pages:229-234 https://dx.doi.org/10.1007/s10165-009-0162-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 19 2009 3 27 03 229-234
allfields_unstemmed	10.1007/s10165-009-0162-4 doi (DE-627)SPR009021809 (SPR)s10165-009-0162-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Horikoshi, Masanobu verfasserin aut Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics. Infliximab (dpeaa)DE-He213 Mizoribine (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Ito, Satoshi verfasserin aut Ishikawa, Mizue verfasserin aut Umeda, Naoto verfasserin aut Kondo, Yuya verfasserin aut Tsuboi, Hiroto verfasserin aut Hayashi, Taichi verfasserin aut Goto, Daisuke verfasserin aut Matsumoto, Isao verfasserin aut Sumida, Takayuki verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 19(2009), 3 vom: 27. März, Seite 229-234 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:19 year:2009 number:3 day:27 month:03 pages:229-234 https://dx.doi.org/10.1007/s10165-009-0162-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 19 2009 3 27 03 229-234
allfieldsGer	10.1007/s10165-009-0162-4 doi (DE-627)SPR009021809 (SPR)s10165-009-0162-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Horikoshi, Masanobu verfasserin aut Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics. Infliximab (dpeaa)DE-He213 Mizoribine (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Ito, Satoshi verfasserin aut Ishikawa, Mizue verfasserin aut Umeda, Naoto verfasserin aut Kondo, Yuya verfasserin aut Tsuboi, Hiroto verfasserin aut Hayashi, Taichi verfasserin aut Goto, Daisuke verfasserin aut Matsumoto, Isao verfasserin aut Sumida, Takayuki verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 19(2009), 3 vom: 27. März, Seite 229-234 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:19 year:2009 number:3 day:27 month:03 pages:229-234 https://dx.doi.org/10.1007/s10165-009-0162-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 19 2009 3 27 03 229-234
allfieldsSound	10.1007/s10165-009-0162-4 doi (DE-627)SPR009021809 (SPR)s10165-009-0162-4-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Horikoshi, Masanobu verfasserin aut Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics. Infliximab (dpeaa)DE-He213 Mizoribine (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Ito, Satoshi verfasserin aut Ishikawa, Mizue verfasserin aut Umeda, Naoto verfasserin aut Kondo, Yuya verfasserin aut Tsuboi, Hiroto verfasserin aut Hayashi, Taichi verfasserin aut Goto, Daisuke verfasserin aut Matsumoto, Isao verfasserin aut Sumida, Takayuki verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 19(2009), 3 vom: 27. März, Seite 229-234 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:19 year:2009 number:3 day:27 month:03 pages:229-234 https://dx.doi.org/10.1007/s10165-009-0162-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 19 2009 3 27 03 229-234
language	English
source	Enthalten in Modern rheumatology 19(2009), 3 vom: 27. März, Seite 229-234 volume:19 year:2009 number:3 day:27 month:03 pages:229-234
sourceStr	Enthalten in Modern rheumatology 19(2009), 3 vom: 27. März, Seite 229-234 volume:19 year:2009 number:3 day:27 month:03 pages:229-234
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Infliximab Mizoribine Rheumatoid arthritis
dewey-raw	610
isfreeaccess_bool	false
container_title	Modern rheumatology
authorswithroles_txt_mv	Horikoshi, Masanobu @@aut@@ Ito, Satoshi @@aut@@ Ishikawa, Mizue @@aut@@ Umeda, Naoto @@aut@@ Kondo, Yuya @@aut@@ Tsuboi, Hiroto @@aut@@ Hayashi, Taichi @@aut@@ Goto, Daisuke @@aut@@ Matsumoto, Isao @@aut@@ Sumida, Takayuki @@aut@@
publishDateDaySort_date	2009-03-27T00:00:00Z
hierarchy_top_id	320627497
dewey-sort	3610
id	SPR009021809
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009021809</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519115549.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2009 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-009-0162-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009021809</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-009-0162-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Horikoshi, Masanobu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Infliximab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mizoribine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rheumatoid arthritis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ito, Satoshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishikawa, Mizue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Umeda, Naoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kondo, Yuya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsuboi, Hiroto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hayashi, Taichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goto, Daisuke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsumoto, Isao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sumida, Takayuki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">19(2009), 3 vom: 27. März, Seite 229-234</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:3</subfield><subfield code="g">day:27</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:229-234</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-009-0162-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_711</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2009</subfield><subfield code="e">3</subfield><subfield code="b">27</subfield><subfield code="c">03</subfield><subfield code="h">229-234</subfield></datafield></record></collection>
author	Horikoshi, Masanobu
spellingShingle	Horikoshi, Masanobu ddc 610 bkl 44.83 misc Infliximab misc Mizoribine misc Rheumatoid arthritis Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab
authorStr	Horikoshi, Masanobu
ppnlink_with_tag_str_mv	@@773@@(DE-627)320627497
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1439-7609
topic_title	610 ASE 44.83 bkl Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab Infliximab (dpeaa)DE-He213 Mizoribine (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213
topic	ddc 610 bkl 44.83 misc Infliximab misc Mizoribine misc Rheumatoid arthritis
topic_unstemmed	ddc 610 bkl 44.83 misc Infliximab misc Mizoribine misc Rheumatoid arthritis
topic_browse	ddc 610 bkl 44.83 misc Infliximab misc Mizoribine misc Rheumatoid arthritis
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Modern rheumatology
hierarchy_parent_id	320627497
dewey-tens	610 - Medicine & health
hierarchy_top_title	Modern rheumatology
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)320627497 (DE-600)2023498-3
title	Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab
ctrlnum	(DE-627)SPR009021809 (SPR)s10165-009-0162-4-e
title_full	Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab
author_sort	Horikoshi, Masanobu
journal	Modern rheumatology
journalStr	Modern rheumatology
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2009
contenttype_str_mv	txt
container_start_page	229
author_browse	Horikoshi, Masanobu Ito, Satoshi Ishikawa, Mizue Umeda, Naoto Kondo, Yuya Tsuboi, Hiroto Hayashi, Taichi Goto, Daisuke Matsumoto, Isao Sumida, Takayuki
container_volume	19
class	610 ASE 44.83 bkl
format_se	Elektronische Aufsätze
author-letter	Horikoshi, Masanobu
doi_str_mv	10.1007/s10165-009-0162-4
dewey-full	610
author2-role	verfasserin
title_sort	efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab
title_auth	Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab
abstract	Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics.
abstractGer	Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics.
abstract_unstemmed	Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333
container_issue	3
title_short	Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab
url	https://dx.doi.org/10.1007/s10165-009-0162-4
remote_bool	true
author2	Ito, Satoshi Ishikawa, Mizue Umeda, Naoto Kondo, Yuya Tsuboi, Hiroto Hayashi, Taichi Goto, Daisuke Matsumoto, Isao Sumida, Takayuki
author2Str	Ito, Satoshi Ishikawa, Mizue Umeda, Naoto Kondo, Yuya Tsuboi, Hiroto Hayashi, Taichi Goto, Daisuke Matsumoto, Isao Sumida, Takayuki
ppnlink	320627497
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s10165-009-0162-4
up_date	2024-07-04T00:21:17.263Z
_version_	1803605746402721792
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009021809</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519115549.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2009 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-009-0162-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009021809</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-009-0162-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Horikoshi, Masanobu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The efficacy of infliximab, a chimeric antibody against tumor necrosis factor-α used to treat patients with rheumatoid arthritis (RA), tends to decrease as patients develop human antichimeric antibody against infliximab (HACA). The clinical study reported here was designed to evaluate the efficacy of mizoribine (MZR) pulse therapy in patients who show a reduced or insufficient response to infliximab. Ten RA patients who had active arthritis despite infliximab therapy were treated with MZR pulse therapy at a dose of 100 mg MZR and methotrexate (MTX) and the disease activity assessed at baseline and at weeks 4–8, 12–16, and 20–24. The dose was increased to 150 mg in those patients who showed an insufficient response to MZR. The mean 28-joint disease activity score (DAS28) at weeks 12–16 and 20–24 of therapy was significantly lower than that at baseline. A moderate or good European League against Rheumatism (EULAR) response was achieved in seven patients (70%) at weeks 12–16 and in five patients (50%) at weeks 20–24. The dose of 150 mg MZR was effective in one of the three patients who showed an insufficient response to pulse therapy with 100 mg MZR. Based on these results, we propose that MZR pulse therapy should be attempted before the patient is switched to other biologics.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Infliximab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mizoribine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rheumatoid arthritis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ito, Satoshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishikawa, Mizue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Umeda, Naoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kondo, Yuya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsuboi, Hiroto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hayashi, Taichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goto, Daisuke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsumoto, Isao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sumida, Takayuki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">19(2009), 3 vom: 27. März, Seite 229-234</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:3</subfield><subfield code="g">day:27</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:229-234</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-009-0162-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_711</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2009</subfield><subfield code="e">3</subfield><subfield code="b">27</subfield><subfield code="c">03</subfield><subfield code="h">229-234</subfield></datafield></record></collection>
score	7.40042

Nicht das Richtige dabei?

Schreiben Sie uns!

Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?